NAD+ vs NMN: How NAD+ May Support Cellular Energy Compared to Precursors

Understanding NAD+ and Its Cellular Role

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells. It participates in a range of biochemical reactions, particularly those related to metabolic activity and cellular signaling.

• ATP Production: NAD+ plays a role in energy-generating pathways such as glycolysis, the Krebs cycle, and oxidative phosphorylation.
• Redox Reactions: It contributes to oxidation-reduction reactions that help maintain the cellular redox state.
• Cellular Signaling: NAD+ acts as a substrate for enzymes involved in stress responses and DNA maintenance.

Ongoing research in cell and animal models is exploring how NAD+ availability may affect mitochondrial function, but further studies are needed to understand these effects in humans.

‍

NAD+ Changes

Research has observed that NAD+ concentrations may decline with age in various tissues, including in human and animal models. However, findings vary depending on the tissue studied, and individual variability is significant. Several hypotheses have been proposed to explain potential NAD+ decline:

• Enzyme Activity: Enzymes such as CD38 and PARP1 may use more NAD+ under stress or with age-related changes.
• Inflammatory Signals: Inflammatory responses have been associated with increased NAD+ turnover in some models.
• DNA Maintenance: Greater activity of DNA-repair enzymes that rely on NAD+ may influence intracellular NAD+ availability.

These associations remain under active investigation, and their clinical relevance in humans is not yet fully understood.

‍

Emerging Areas of Research

Researchers are exploring how NAD+ precursors such as NMN and NR convert into NAD+ through cellular pathways. These investigations help illuminate the metabolic processes that regulate NAD+ availability inside cells.

In humans and other mammals, NAD+ levels are primarily maintained through a recycling process known as the salvage pathway. This system allows cells to regenerate NAD+ from nicotinamide (NAM), a byproduct of NAD+ metabolism.

Key steps in this pathway include:

• Conversion of NAM to NMN via the enzyme NAMPT
• Conversion of NMN to NAD+ via the enzyme NMNAT

Scientific estimates suggest that the salvage pathway accounts for the majority of NAD+ production in cells. Understanding these processes may help guide future research into NAD+ energy, fatigue levels, cellular metabolism, and DNA repair.

‍

How NAD+ Precursors Convert Within the Body

Understanding how precursors such as NMN and NR may convert to NAD+ in the body provides insight into their potential role in supporting energy metabolism. These compounds are part of a broader scientific effort to understand how cells recycle and maintain NAD+ through metabolic pathways like the salvage pathway.

The NAD+ Salvage Pathway: A Key Recycling System

In humans and other mammals, the primary mechanism for maintaining intracellular NAD+ levels is known as the salvage pathway. This recycling process enables cells to regenerate NAD+ using nicotinamide (NAM), a byproduct of NAD+ consumption.

Key enzymatic steps in this pathway include:

• NAM → NMN via NAMPT (nicotinamide phosphoribosyltransferase)
• NMN → NAD+ via NMNAT (nicotinamide mononucleotide adenylyltransferase)

It is estimated that this salvage cycle accounts for the majority of NAD+ production in human cells.

NMN vs. NR: Distinct Routes of Conversion

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors that follow distinct biological conversion pathways. Their structural differences affect how they are absorbed and processed in the body.

• NR enters cells via nucleoside transporters and is then converted into NMN, which is subsequently used to generate NAD+.
• NMN, because of its phosphate group, may not be as readily transported into cells. Some research suggests that enzymes outside cells may first convert NMN to NR, which can then be absorbed and reconverted internally.

Early-stage studies in animals and small human trials have investigated differences in how NR and NMN affect circulating NAD+ levels. However, findings are inconclusive and require validation through larger, placebo-controlled clinical trials before comparative conclusions can be drawn.

Gut Microbiota and Precursor Metabolism

Emerging research suggests that the gut microbiome may influence how NAD+ precursors such as NR and NAM are processed in the body. Some gut bacteria appear capable of converting these compounds into alternative metabolites, such as nicotinic acid, which may then enter NAD+ biosynthesis pathways in the liver and kidneys.

These microbial interactions are being studied to better understand how individual biology might affect NAD+ metabolism. While this area of research is still developing, scientists are exploring whether microbiome composition could one day inform personalized approaches to nutritional or metabolic interventions.

‍

Comparing NAD+ and NMN: Considerations in Cellular Uptake and Metabolism

NAD+, NMN, and NR are all connected within the body’s NAD+ metabolic system but differ in chemical structure, absorption pathways, and cellular processing. These distinctions are the focus of ongoing biochemical and clinical research, which aims to understand how these compounds influence intracellular NAD+ availability without yet establishing consistent clinical outcomes in humans.

Transport Limitations of NMN and NR

Research has suggested that NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) follow distinct cellular uptake and processing routes.

NR is absorbed via specialized nucleoside transporters known as equilibrative nucleoside transporters (ENTs) and is subsequently phosphorylated by nicotinamide riboside kinases (NRKs) to form NMN. That NMN is then converted into NAD+ via nicotinamide mononucleotide adenylyltransferases (NMNATs).

NMN, due to its phosphate group and larger molecular structure, is not easily transported into most cells in its unmodified form. However, enzymes such as CD73 may convert NMN to NR extracellularly, facilitating uptake through the same transporters used by NR.

These routes are part of the salvage pathway, the primary system by which human cells regenerate NAD+ from precursor molecules. The biological efficiency of each precursor’s conversion into NAD+ varies depending on individual factors such as enzyme activity, tissue type, and microbiome composition.

Variability in Processing and Metabolism

Once inside the body, NR and NMN are metabolized differently based on factors such as:

• Enzymatic activity (e.g., NRKs, NMNATs, CD38)
• Gut microbiome influence
• Individual metabolic conditions

Reduced Forms: NMNH and DNR

Recently, researchers have explored reduced forms of NAD+ precursors such as:

• NMNH (reduced nicotinamide mononucleotide)
• DNR (dihydronicotinamide riboside)

These compounds have demonstrated enhanced stability or increased NAD+ biosynthesis potential in preclinical laboratory models. However, these early-stage findings are based primarily on in vitro or animal studies. No large-scale human trials have confirmed their safety, efficacy, or relevance to human metabolic health.

Further research is needed to determine whether these reduced forms offer advantages over traditional precursors in clinical settings.

Note: While NAD+, NMN, and NR are being studied for their roles in cellular metabolism, no NAD+ precursor has been approved to treat, prevent, or cure any disease. The differences described here are based on mechanistic and early clinical research. Individuals considering supplementation should consult with a licensed healthcare provider.

NAD+ Injections and Bioavailability

Injectable NAD+ is an investigational method of delivery that bypasses the digestive system and may alter how NAD+ is distributed in the body compared to oral or sublingual formulations. These injections are typically administered under the direction of a licensed medical professional and are not FDA-approved for the treatment or prevention of any medical condition.

Preliminary studies and individual case reports have described potential changes in circulating NAD+ levels following intravenous or intramuscular administration. However, these findings are early-stage and lack consistent validation in placebo-controlled human trials.

There is currently no conclusive evidence supporting the use of injectable NAD+ for cognitive, neurological, metabolic, or energy-related outcomes. As such, these interventions should be considered experimental unless evaluated by a licensed healthcare provider within a regulated clinical setting.

Eden does not offer or endorse injectable NAD+ products. We provide access to licensed healthcare providers who evaluate whether treatment options are appropriate on an individual basis.

‍

Safety, Bioavailability, and Research on NAD+ Precursors

Human Trial Results for NMN and NR

Human clinical trials have observed that oral supplementation with NAD+ precursors such as NMN and NR can lead to increased levels of NAD+ in the bloodstream. For example, a randomized trial involving 80 adults reported elevated NAD+ concentrations after 60 days of NMN use, though changes in functional biomarkers were minimal and inconsistent.

NR has been studied more extensively and appears to be well tolerated in the short term at doses up to 2,000 mg per day. However, across trials, no consistent improvements have been found in metabolic health indicators such as insulin sensitivity, mitochondrial function, or energy output.

Preclinical research has raised questions about the effects of high-dose nicotinamide, including possible impacts on liver enzymes and methylation processes. However, the relevance of these findings to typical human supplementation remains unclear.

Short-term use of NMN and NR is generally considered safe in healthy adults, but long-term safety has not yet been established, as most clinical trials have lasted 8–12 weeks.

Several third-party evaluations have also identified quality control issues in the supplement marketplace. Some NMN and NR products were found to contain lower-than-labeled amounts of active ingredients—or none at all. These findings highlight the importance of purchasing from reputable brands that provide third-party testing and quality assurance.

‍

Conclusion: Understanding the Landscape of NAD+ Supplementation

Scientific research into NAD+ and its precursors, including NMN and NR, is ongoing. While these compounds are integral to cellular NAD+ biosynthesis, the clinical relevance of modifying NAD+ levels in humans is not yet well understood.

Some early-stage human studies have shown that supplementation with NMN or NR can increase blood concentrations of NAD+, but consistent, validated improvements in health outcomes such as energy metabolism, cognitive function, or aging-related markers have not been demonstrated.

Individual responses to supplementation may vary due to multiple factors, including enzyme expression, microbiome diversity, lifestyle habits, and supplement formulation quality. These complexities highlight the need for more rigorous, long-term, placebo-controlled clinical trials.

At Eden, we connect individuals with licensed medical professionals who can evaluate treatment options based on the latest available research and your personal health goals. If you're considering NAD+ precursors or other wellness solutions, it’s important to do so under medical supervision to ensure safety and relevance to your individual biology.

The information in this article is for educational purposes only and does not constitute medical advice. Eden does not manufacture or dispense medications or supplements. Any treatment decisions should be made between a patient and a licensed medical provider. Supplementation outcomes may vary and are not guaranteed.

‍